The final IFN-γ signature that further confirmed the significant correlation with HNSCC response to pembrolizumab from tumor samples obtained from KEYNOTE-012 was also validated on nine types of malignancies (13). The gene discussed is IFNG; the disease is head and neck squamous cell carcinoma.